| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S421402-1ml |
1ml |
现货  |
|
| 别名 | (αR,γS)-γ-[(3-羧基-1-氧丙基)氨基]-α-甲基-[1,1'-联苯] -4-戊酸半钙盐 | AHU377 钙盐 | AHU-377 钙盐 | 4-{[(2S,4R)-1-(4-联苯基)-5-乙氧基-4-甲基-5-氧代-2-戊烷基]氨基}-4-氧代丁酸 | (2R,4S)-5-(联苯-4-基)-4-[(3-羧基丙酰基)氨基]-2-甲基戊酸乙酯 | (2R,4S)-4-[(3-羧基-1-丙酰基)氨基]-4-[(对-联苯基)甲基]-2-甲基丁酸乙酯 | 4-[[(2S,4R)-5-乙氧基-4-甲基-5-氧代-1-(4-联 |
|---|---|
| 英文别名 | 1369773-39-6 | AHU-377 hemicalcium salt | Sacubitril calcium | Sacubitril hemicalcium salt | AHU-377 calcium salt | 8F45HCQ47Q | UNII-8F45HCQ47Q | 4-(((2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl)amino)-4-oxobutanoic acid calcium salt, | calcium;4-[[(2S, |
| 规格或纯度 | 10mM in DMSO |
| 英文名称 | Sacubitril calcium |
| 生化机理 | 膜金属内肽酶（中性溶酶）抑制剂前药。增加ANF诱导的利尿作用，而不影响大鼠的利尿作用。 Sacubitril (AHU377) is a prodrug inhibitor of the membrane metallo-endopeptidase neprilysin. Sacubitril forms half of the heart failure combination drug LCZ696, along with the angiotensin-receptor blocker Valsartan. Sacubitril (AHU377) is cojnverted by esterases into the active inhibitor LBQ657, which prevents neprilysin′s degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides. The AHU377 valsartan combination drug LCZ696 showed a reduction in the risk of cardiovascular death of 20% compared to the standard ACE inhibitor enalapril, and also a 21% drop in the risk of hospitalization. |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Sacubitril (AHU-377) hemicalcium salt 是有效的NEP抑制剂，IC50值为5 nM。Sacubitril hemicalcium salt 是研究心力衰竭药物 LCZ696 的一个组分。 |
| IIUPAC Name | calcium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate |
|---|---|
| INCHI | 1S/2C24H29NO5.Ca/c2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;/h2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);/q;;+2/p-2/t2*17-,21+;/m11./s1 |
| InChi Key | DDLCKLBRBPYKQS-OXXXZDCLSA-L |
| Smiles | CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].[Ca+2] |
| Isomeric SMILES | CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].[Ca+2] |
| PubChem CID | 92045585 |
| 分子量 | 430.52 |
| 敏感性 | 对湿度敏感 |
|---|---|
| 分子量 | 861.000 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 22 |
| 精确质量Exact Mass | 860.356 Da |
| 单同位素质量Monoisotopic Mass | 860.356 Da |
| 拓扑极表面积Topological Polar Surface Area | 191.000 Ų |
| 重原子数Heavy Atom Count | 61 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 544.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 4 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 3 |
首页
400-620-6333
